AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05805007
Drug: ZVS203e
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
Trial: NCT05135793
Drug: Takecab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 20 mg vonoprazan
Trial: NCT05415241
Drug: FB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1.
Trial: NCT05285696
Drug: CSB-111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]-NOTA-hGZP is a PET imaging agent.
Trial: NCT06388564
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids will be administered at protocol defined dose.
Trial: NCT05268016
Drug: ME3183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME3183 capsule
Trial: NCT05268016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT06224036
Drug: JDB0131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.
Trial: NCT04994314
Drug: nCaF2 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
Trial: NCT06224036
Drug: Ethylpyrazine rifampicide (II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
Trial: NCT06446531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet administered once daily
Trial: NCT05092776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
Trial: NCT04886362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Placebo in the first 7 days from symptoms onset.
Trial: NCT04908800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT04789057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o., once daily
Trial: NCT06150417
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
Trial: NCT05277350
Drug: SNIPR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
Trial: NCT05277350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06450275
Drug: Tivicay 50mg, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Dolutegravir 50mg film-coated tablets
Trial: NCT05664061
Drug: ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily inhalation throughout the treatment period
Trial: NCT05664061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily inhalation throughout the treatment period
Trial: NCT06653569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.
Trial: NCT05249621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product containing excipients with no active ingredients
Trial: NCT04533750
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05928689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT06249321
Drug: mFOLFIRINOX plus IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
Trial: NCT02556970
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75mg intraoperatively
Trial: NCT05415644
Drug: hrx0701 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).
Trial: NCT02556970
Drug: 0.25% Levobupivicaine intercostal nerve block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
Trial: NCT05806164
Drug: OnabotulinumtoxinA 100 UNT [Botox]
RxNorm normalized name: onabotulinumtoxinA 100 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
Trial: NCT05071664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a SC injection.
Trial: NCT04624672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
Trial: NCT05728619
Drug: HTMC0435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT04694300
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days.
Trial: NCT04694300
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
Trial: NCT06213324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline delivered intravenously
Trial: NCT05116891
Drug: G/C
RxNorm normalized name: GG/Codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/C/CAN04
Trial: NCT06137911
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered
Trial: NCT06504524
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control arm
Trial: NCT06602167
Drug: Doctor-prescribed treatment
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
Trial: NCT05279417
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Trial: NCT05279417
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg to 25 mg weekly
Trial: NCT06070350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided to the research pharmacy at each of the clinical sites
Trial: NCT06366698
Drug: Venofer 200 MG Per 10 ML Injection
RxNorm normalized name: Venofer 200 MG per 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV every 2 days until the targeted dose
Trial: NCT05138133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion (IV)
Trial: NCT05623761
Drug: BUCCOTHERM® Sensitive Gums with Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
Trial: NCT05623761
Drug: BUCCOTHERM® Sensitive Gums Fluoride-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
Trial: NCT06574503
Drug: GP681 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2X20mg tablets taken orally
Trial: NCT06574503
Drug: GP681 Simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching GP681 40mg
Trial: NCT05086666
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor.
Trial: NCT05691621
Drug: Standard Reagents, Whole Blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive standard treatment, only their blood and urine samples are needed
Trial: NCT05189288
Drug: D418 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT05189288
Drug: CKD-388 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT04804371
Drug: F18-FDG
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate FDG uptake
Trial: NCT00002379
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06599619
Drug: Single agent, adjuvant anti-PD1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of the following Single-agent, adjuvant anti-PD1 therapies:~Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.~Dose = 240 mg IV every 2 weeks/480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.~Dose = 200 mg IV every 3 weeks/ 400 mg every 6 weeks
Trial: NCT04441073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
Trial: NCT06576921
Drug: Placebo combined with Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
Trial: NCT04893993
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets. 300mg/tablet. Dosage depends on gender and weight
Trial: NCT04893993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets. Same number of tablets as Thiamine
Trial: NCT05984147
Drug: AUR108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Days dosing, and 4 days no dose in a week
Trial: NCT05022927
Drug: ERY974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERY974 vial
Trial: NCT05132595
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Trial: NCT05073835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06367426
Drug: DDN-A-0101 (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture
Trial: NCT06367426
Drug: Placebo (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture
Trial: NCT06367426
Drug: Placebo (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture
Trial: NCT05132595
Drug: Ketorolac at high dose
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
Trial: NCT05132595
Drug: Ketorolac at low dose
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
Trial: NCT06416969
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05198323
Drug: LT3001 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT05198323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT06645821
Drug: EVO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVO101 topical cream 0.1%
Trial: NCT06326281
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
Trial: NCT02127736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05995249
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin tablets
Trial: NCT05995249
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin capsules
Trial: NCT05602129
Drug: HSK36273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK36273
Trial: NCT05602129
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium
Trial: NCT05342428
Drug: TLL018 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Trial: NCT05887479
Drug: %0,9 NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: %0,9 NaCl
Trial: NCT05649943
Drug: APA + ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment.
Trial: NCT05329727
Drug: Angiotensin receptor neprilysin inhibitor (ARNI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
Trial: NCT05329727
Drug: Renin-Angiotensin System Inhibitor (RAS inhibitor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
Trial: NCT06474650
Drug: LPM3770164 sustained release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of 30 mg of LPM3770164 sustained release tablet
Trial: NCT04544943
Drug: BioLexa- Cohort 1
RxNorm normalized name: BIOLEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
Trial: NCT04544943
Drug: BioLexa- Cohort 2
RxNorm normalized name: BIOLEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
Trial: NCT04544943
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily (BID) application of Gentamicin for 14 days
Trial: NCT05029609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Trial: NCT05192382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablets, once daily by mouth
Trial: NCT04601883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo tablets. Placebo is identical to the active intervention.
Trial: NCT06235697
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assigned at enrollment
Trial: NCT04964583
Drug: Hydroxychloroquine with Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
Trial: NCT06320353
Drug: Keytruda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)